| Reference |
|---|
Lah S, Kim S, Kang I, Kim H, Hupperetz C, Jung H, et al. Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locus. J Immunother Cancer. 2023;11: pubmed publisher |
Zhu X, Li Q, George V, Spanoudis C, Gilkes C, Shrestha N, et al. A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice. Front Immunol. 2023;14:1114802 pubmed publisher |
Estep B, Kuhlmann C, Osuka S, Suryavanshi G, Nagaoka Kamata Y, Samuel C, et al. Skewed fate and hematopoiesis of CD34+ HSPCs in umbilical cord blood amid the COVID-19 pandemic. iScience. 2022;25:105544 pubmed publisher |
VanDyke D, Iglesias M, Tomala J, Young A, Smith J, Perry J, et al. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep. 2022;41:111478 pubmed publisher |
Reuschl A, Mesner D, Shivkumar M, Whelan M, Pallett L, Guerra Assun xe7 xe3 o J, et al. HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. Cell Rep. 2022;39:110650 pubmed publisher |
Yen M, Ren J, Liu Q, Glassman C, Sheahan T, Picton L, et al. Facile discovery of surrogate cytokine agonists. Cell. 2022;185:1414-1430.e19 pubmed publisher |
Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, et al. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J Immunother Cancer. 2022;10: pubmed publisher |
Sulejmani O, Grunewald L, Andersch L, Schwiebert S, Klaus A, Winkler A, et al. Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis. Cancers (Basel). 2021;13: pubmed publisher |
Leclercq G, Haegel H, Schneider A, Giusti A, Marrer Berger E, Boetsch C, et al. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. J Immunother Cancer. 2021;9: pubmed publisher |
Zirngibl F, Ivasko S, Grunewald L, Klaus A, Schwiebert S, Ruf P, et al. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. J Immunother Cancer. 2021;9: pubmed publisher |
Xie G, Luo X, Ma T, Frouard J, Neidleman J, Hoh R, et al. Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. Cell Rep. 2021;35:109038 pubmed publisher |
Hsiue E, Wright K, Douglass J, Hwang M, Mog B, Pearlman A, et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371: pubmed publisher |
Glassman C, Mathiharan Y, Jude K, Su L, Panova O, Lupardus P, et al. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell. 2021;184:983-999.e24 pubmed publisher |
Peng S, Zaretsky J, Ng A, Chour W, Bethune M, Choi J, et al. Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. Cell Rep. 2019;28:2728-2738.e7 pubmed publisher |
Ling Y, Krishnan S, Chan C, Diep H, Ferens D, Chin Dusting J, et al. Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension. Pharmacol Res. 2017;116:77-86 pubmed publisher |
